PRF1 and viral infectious disease: Immunomodulatory therapies for viral infections carry the risk of increasing bystander immune responses and cytotoxic tissue damage; however, we did not detect any significant increase of CD107a mobilization to the cell membrane of perforin-producing T cells, markers of degranulation and cytotoxicity, respectively (S4H Fig).